AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
AN2 Therapeutics, Inc. (ANTX)
US:NYSE Investor Relations:
ir.antheminc.com
Company Research
Source: Business Wire
Substantial clinical evidence provides rationale to initiate Phase 2 study in PVPhase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer characterized by overproduction of red blood cells in the bone marrow. This overproduction increases hematocrit which can lead to serious medical complications, including arterial and venous thromboembolic events.The Company’s decision to pursue PV is supported by data from multiple clinical trials of oral epetraborole in health
Show less
Read more
Impact Snapshot
Event Time:
ANTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANTX alerts
High impacting AN2 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ANTX
News
- AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare ConferenceBusiness Wire
- AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung DiseaseBusiness Wire
ANTX
Earnings
- 5/13/25 - Miss
ANTX
Sec Filings
- 3/5/26 - Form 4
- 2/23/26 - Form 4
- 2/23/26 - Form 4
- ANTX's page on the SEC website